Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Isolation and characterization of canine natural killer cells.

Michael HT, Ito D, McCullar V, Zhang B, Miller JS, Modiano JF.

Vet Immunol Immunopathol. 2013 Sep 15;155(3):211-7. doi: 10.1016/j.vetimm.2013.06.013. Epub 2013 Jun 28.

2.

Ex vivo expansion of natural killer cells for clinical applications.

Klingemann HG, Martinson J.

Cytotherapy. 2004;6(1):15-22.

PMID:
14985163
3.

Generation of recombinant canine interleukin-15 and evaluation of its effects on the proliferation and function of canine NK cells.

Lee SH, Shin DJ, Kim SK.

Vet Immunol Immunopathol. 2015 May 15;165(1-2):1-13. doi: 10.1016/j.vetimm.2015.04.002. Epub 2015 Apr 8.

PMID:
25890849
4.

Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1031-8. doi: 10.1016/j.bbmt.2008.06.016.

5.

Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18.

Lauwerys BR, Garot N, Renauld JC, Houssiau FA.

J Immunol. 2000 Aug 15;165(4):1847-53.

6.
7.
8.

[Ex vivo expansion of highly purified NK cells from human peripheral blood].

Li XH, Ma J, Wang FF, Dou LP, Li M, Gao CJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Apr;15(2):373-7. Chinese.

PMID:
17493350
9.
10.
11.

Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.

Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, Schiavetti F, Bertone S, Moretta A, Moretta L.

Eur J Immunol. 1997 Jun;27(6):1374-80.

PMID:
9209487
13.
14.

Interleukin 2-induced proliferation of murine natural killer cells in vivo.

Biron CA, Young HA, Kasaian MT.

J Exp Med. 1990 Jan 1;171(1):173-88.

15.

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

Decot V, Voillard L, Latger-Cannard V, Aissi-Rothé L, Perrier P, Stoltz JF, Bensoussan D.

Exp Hematol. 2010 May;38(5):351-62. doi: 10.1016/j.exphem.2010.02.006. Epub 2010 Feb 19.

PMID:
20172016
16.

Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.

Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG.

J Immunol. 2001 Sep 15;167(6):3129-38.

17.

Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).

Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.

Exp Hematol. 1998 Feb;26(2):93-9.

PMID:
9472798
18.

Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.

Helfand SC, Soergel SA, Modiano JF, Hank JA, Sondel PM.

Cancer Biother. 1994 Fall;9(3):237-44.

PMID:
7820185
19.

Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.

Condiotti R, Zakai YB, Barak V, Nagler A.

Exp Hematol. 2001 Jan;29(1):104-13.

PMID:
11164111
20.
Items per page

Supplemental Content

Write to the Help Desk